Related Experiment Videos
Chemotherapy enhances endothelial cell reactivity to platelets
M C Bertomeu1, S Gallo, D Lauri
1McMaster University, Department of Pathology, Hamilton, Ontario, Canada.
Clinical & Experimental Metastasis
|November 1, 1990
Summary
Chemotherapy increases thrombosis risk in breast cancer patients by enhancing endothelial cell reactivity. This effect is mediated by interleukin-1, suggesting a key mechanism in chemotherapy-induced thrombosis.
Area of Science:
- Oncology
- Hematology
- Cell Biology
Background:
- Chemotherapy is linked to thrombosis in breast cancer patients.
- The precise mechanisms underlying this increased thrombotic risk are not fully understood.
- Endothelial cell dysfunction is a potential contributor.
Purpose of the Study:
- To investigate if chemotherapy affects endothelial cell reactivity.
- To determine the role of plasma factors in chemotherapy-induced endothelial cell changes.
- To elucidate the molecular mechanisms linking chemotherapy to thrombosis.
Main Methods:
- Incubating cultured human endothelial cells with plasma from breast cancer patients undergoing chemotherapy.
- Assessing endothelial cell reactivity to platelets using isotopic methods.
- Analyzing the effect of heat inactivation, interleukin-1 levels, and specific peptide/antibody inhibition.
Main Results:
- Post-chemotherapy plasma significantly increased endothelial cell reactivity to platelets.
- This effect persisted after drug clearance but was abolished by heat inactivation.
- Increased reactivity correlated with interleukin-1 levels and was inhibited by anti-vitronectin receptor antibody and GRGDS peptide.
Conclusions:
- Chemotherapy alters endothelial cell reactivity, potentially via induced interleukin-1 release.
- Interleukin-1 may upregulate adhesion molecules on endothelial cells, promoting platelet interaction.
- This pathway offers a mechanistic explanation for chemotherapy-associated thrombosis in breast cancer.